Chronic lymphocytic leukaemia
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in de...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Hallek, Michael [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Umfang: |
14 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Effects of shape functions on flexural–torsional buckling of fixed circular arches - Dou, Chao ELSEVIER, 2013, London [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:391 ; year:2018 ; number:10129 ; day:14 ; month:04 ; pages:1524-1537 ; extent:14 |
| Links: |
|---|
| DOI / URN: |
10.1016/S0140-6736(18)30422-7 |
|---|
| Katalog-ID: |
ELV042662257 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042662257 | ||
| 003 | DE-627 | ||
| 005 | 20230626002005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(18)30422-7 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000249A.pica |
| 035 | |a (DE-627)ELV042662257 | ||
| 035 | |a (ELSEVIER)S0140-6736(18)30422-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 690 |q VZ |
| 084 | |a 38.38 |2 bkl | ||
| 084 | |a 56.20 |2 bkl | ||
| 084 | |a 56.11 |2 bkl | ||
| 100 | 1 | |a Hallek, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic lymphocytic leukaemia |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 14 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. | ||
| 520 | |a Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. | ||
| 700 | 1 | |a Shanafelt, Tait D |4 oth | |
| 700 | 1 | |a Eichhorst, Barbara |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Dou, Chao ELSEVIER |t Effects of shape functions on flexural–torsional buckling of fixed circular arches |d 2013 |g London [u.a.] |w (DE-627)ELV007685041 |
| 773 | 1 | 8 | |g volume:391 |g year:2018 |g number:10129 |g day:14 |g month:04 |g pages:1524-1537 |g extent:14 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0140-6736(18)30422-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-GEO | ||
| 936 | b | k | |a 38.38 |j Seismologie |q VZ |
| 936 | b | k | |a 56.20 |j Ingenieurgeologie |j Bodenmechanik |q VZ |
| 936 | b | k | |a 56.11 |j Baukonstruktion |q VZ |
| 951 | |a AR | ||
| 952 | |d 391 |j 2018 |e 10129 |b 14 |c 0414 |h 1524-1537 |g 14 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m h mh |
|---|---|
| matchkey_str |
hallekmichaelshanafelttaitdeichhorstbarb:2018----:hoilmhctc |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
38.38 56.20 56.11 |
| publishDate |
2018 |
| allfields |
10.1016/S0140-6736(18)30422-7 doi GBV00000000000249A.pica (DE-627)ELV042662257 (ELSEVIER)S0140-6736(18)30422-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Hallek, Michael verfasserin aut Chronic lymphocytic leukaemia 2018transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Shanafelt, Tait D oth Eichhorst, Barbara oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 https://doi.org/10.1016/S0140-6736(18)30422-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 391 2018 10129 14 0414 1524-1537 14 045F 610 |
| spelling |
10.1016/S0140-6736(18)30422-7 doi GBV00000000000249A.pica (DE-627)ELV042662257 (ELSEVIER)S0140-6736(18)30422-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Hallek, Michael verfasserin aut Chronic lymphocytic leukaemia 2018transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Shanafelt, Tait D oth Eichhorst, Barbara oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 https://doi.org/10.1016/S0140-6736(18)30422-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 391 2018 10129 14 0414 1524-1537 14 045F 610 |
| allfields_unstemmed |
10.1016/S0140-6736(18)30422-7 doi GBV00000000000249A.pica (DE-627)ELV042662257 (ELSEVIER)S0140-6736(18)30422-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Hallek, Michael verfasserin aut Chronic lymphocytic leukaemia 2018transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Shanafelt, Tait D oth Eichhorst, Barbara oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 https://doi.org/10.1016/S0140-6736(18)30422-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 391 2018 10129 14 0414 1524-1537 14 045F 610 |
| allfieldsGer |
10.1016/S0140-6736(18)30422-7 doi GBV00000000000249A.pica (DE-627)ELV042662257 (ELSEVIER)S0140-6736(18)30422-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Hallek, Michael verfasserin aut Chronic lymphocytic leukaemia 2018transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Shanafelt, Tait D oth Eichhorst, Barbara oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 https://doi.org/10.1016/S0140-6736(18)30422-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 391 2018 10129 14 0414 1524-1537 14 045F 610 |
| allfieldsSound |
10.1016/S0140-6736(18)30422-7 doi GBV00000000000249A.pica (DE-627)ELV042662257 (ELSEVIER)S0140-6736(18)30422-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Hallek, Michael verfasserin aut Chronic lymphocytic leukaemia 2018transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. Shanafelt, Tait D oth Eichhorst, Barbara oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 https://doi.org/10.1016/S0140-6736(18)30422-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 391 2018 10129 14 0414 1524-1537 14 045F 610 |
| language |
English |
| source |
Enthalten in Effects of shape functions on flexural–torsional buckling of fixed circular arches London [u.a.] volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 |
| sourceStr |
Enthalten in Effects of shape functions on flexural–torsional buckling of fixed circular arches London [u.a.] volume:391 year:2018 number:10129 day:14 month:04 pages:1524-1537 extent:14 |
| format_phy_str_mv |
Article |
| bklname |
Seismologie Ingenieurgeologie Bodenmechanik Baukonstruktion |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| authorswithroles_txt_mv |
Hallek, Michael @@aut@@ Shanafelt, Tait D @@oth@@ Eichhorst, Barbara @@oth@@ |
| publishDateDaySort_date |
2018-01-14T00:00:00Z |
| hierarchy_top_id |
ELV007685041 |
| dewey-sort |
3610 |
| id |
ELV042662257 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042662257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002005.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S0140-6736(18)30422-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000249A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042662257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0140-6736(18)30422-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.20</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hallek, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chronic lymphocytic leukaemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shanafelt, Tait D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eichhorst, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Dou, Chao ELSEVIER</subfield><subfield code="t">Effects of shape functions on flexural–torsional buckling of fixed circular arches</subfield><subfield code="d">2013</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV007685041</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:391</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:10129</subfield><subfield code="g">day:14</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1524-1537</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S0140-6736(18)30422-7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GEO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.38</subfield><subfield code="j">Seismologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.20</subfield><subfield code="j">Ingenieurgeologie</subfield><subfield code="j">Bodenmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.11</subfield><subfield code="j">Baukonstruktion</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">391</subfield><subfield code="j">2018</subfield><subfield code="e">10129</subfield><subfield code="b">14</subfield><subfield code="c">0414</subfield><subfield code="h">1524-1537</subfield><subfield code="g">14</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Hallek, Michael |
| spellingShingle |
Hallek, Michael ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 Chronic lymphocytic leukaemia |
| authorStr |
Hallek, Michael |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007685041 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Chronic lymphocytic leukaemia |
| topic |
ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 |
| topic_unstemmed |
ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 |
| topic_browse |
ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t d s td tds b e be |
| hierarchy_parent_title |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| hierarchy_parent_id |
ELV007685041 |
| dewey-tens |
610 - Medicine & health 690 - Building & construction |
| hierarchy_top_title |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007685041 |
| title |
Chronic lymphocytic leukaemia |
| ctrlnum |
(DE-627)ELV042662257 (ELSEVIER)S0140-6736(18)30422-7 |
| title_full |
Chronic lymphocytic leukaemia |
| author_sort |
Hallek, Michael |
| journal |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| journalStr |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
1524 |
| author_browse |
Hallek, Michael |
| container_volume |
391 |
| physical |
14 |
| class |
610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Hallek, Michael |
| doi_str_mv |
10.1016/S0140-6736(18)30422-7 |
| dewey-full |
610 690 |
| title_sort |
chronic lymphocytic leukaemia |
| title_auth |
Chronic lymphocytic leukaemia |
| abstract |
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. |
| abstractGer |
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. |
| abstract_unstemmed |
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO |
| container_issue |
10129 |
| title_short |
Chronic lymphocytic leukaemia |
| url |
https://doi.org/10.1016/S0140-6736(18)30422-7 |
| remote_bool |
true |
| author2 |
Shanafelt, Tait D Eichhorst, Barbara |
| author2Str |
Shanafelt, Tait D Eichhorst, Barbara |
| ppnlink |
ELV007685041 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/S0140-6736(18)30422-7 |
| up_date |
2024-07-06T16:46:22.259Z |
| _version_ |
1803848916415807488 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042662257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002005.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S0140-6736(18)30422-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000249A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042662257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0140-6736(18)30422-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.20</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hallek, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chronic lymphocytic leukaemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shanafelt, Tait D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eichhorst, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Dou, Chao ELSEVIER</subfield><subfield code="t">Effects of shape functions on flexural–torsional buckling of fixed circular arches</subfield><subfield code="d">2013</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV007685041</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:391</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:10129</subfield><subfield code="g">day:14</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1524-1537</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S0140-6736(18)30422-7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GEO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.38</subfield><subfield code="j">Seismologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.20</subfield><subfield code="j">Ingenieurgeologie</subfield><subfield code="j">Bodenmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.11</subfield><subfield code="j">Baukonstruktion</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">391</subfield><subfield code="j">2018</subfield><subfield code="e">10129</subfield><subfield code="b">14</subfield><subfield code="c">0414</subfield><subfield code="h">1524-1537</subfield><subfield code="g">14</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4028225 |